Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1810631 in the Blood
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT05833139
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05822440
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT05797753
- Locations
- 🇺🇸
Nucleus Network-Site Number:8400001, Saint Paul, Minnesota, United States
A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05789342
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT05745701
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 28
- Registration Number
- NCT05720767
- Locations
- 🇺🇸
PPD Austin, Austin, Texas, United States
A Study of IBI351 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05699993
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT05691699
- Locations
- 🇺🇸
Acpru /Id# 251279, Grayslake, Illinois, United States
A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT05685719
- Locations
- 🇨🇳
Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang, China
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 100
- Registration Number
- NCT05679388
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.